Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal-Reference-Cited by-同舟云学术

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal

Published:2018-11-08 Issue:8 Volume:219 Page:1187-1197
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Venkatraman Navin¹,Ndiaye Birahim Pierre²,Bowyer Georgina¹,Wade Djibril²,Sridhar Saranya¹,Wright Daniel¹,Powlson Jonathan¹,Ndiaye Ibrahima²,Dièye Siry²,Thompson Craig¹,Bakhoum Momar²,Morter Richard¹,Capone Stefania³,Del Sorbo Mariarosaria³,Jamieson Sophie¹,Rampling Tommy¹,Datoo Mehreen¹,Roberts Rachel¹,Poulton Ian¹,Griffiths Oliver¹,Ballou W Ripley⁴,Roman François⁴,Lewis David J M⁵,Lawrie Alison¹,Imoukhuede Egeruan¹,Gilbert Sarah C¹,Dieye Tandakha N²,Ewer Katie J¹^ORCID,Mboup Souleymane²,Hill Adrian V S¹

Affiliation:

1. Jenner Institute, University of Oxford, United Kingdom

2. Centre Hospitalier Universitaire le Dantec, Dakar, Senegal

3. ReiThera Srl, Rome, Italy

4. GlaxoSmithKline Biologicals, Rixensart, Belgium

5. National Institute for Health Research/Imperial Clinical Research Facility, Hammersmith Hospital, London, United Kingdom

Funder

the Medical Research Council

Department for International Development

European and Developing Countries Clinical Trials Partnership

European Commission Horizon 2020

Publisher